Jupiter Neurosciences, Inc. Appoints Kristopher Fishman And Sanjiv Lal To The Nugevia Advisory Board To Strengthen Nutraceutical Market Strategy

Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company developing its patented resveratrol-based platform JOTROL™, announced that Kristopher Fishman and Sanjiv Lal have been appointed to the Nugevia™ Advisory Board. Kristopher Fishman and Sanjiv Lal bring direct experience working with compounding pharmacies and wellness distribution channels—an area that Jupiter estimates represents more than $1.5 billion in combined U.S. nutraceutical sales.

Nugevia™ is the company’s consumer longevity product line and uses the same JOTROL™ micellar delivery technology that supports Jupiter’s clinical programs, including its FDA-cleared Phase IIa clinical trial for Parkinson’s disease. The Nugevia™ line currently includes three formulations designed for different health needs: PWR for mitochondrial support, MND for cognitive function, and GLO for skin vitality. These products are available directly to consumers through the company’s website, and Jupiter is now expanding distribution into practitioner-led channels, where the line’s clinical-grade bioavailability may offer a competitive advantage.

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, noted that both new advisory board members have meaningful experience in the environments where demand for Nugevia™ is strongest. He explained that compounding pharmacies and wellness centers often assess scientific evidence before recommending products and that this makes JOTROL’s published bioavailability data—and its potential benefits in inflammation and mitochondrial function—particularly compelling.